Biotech company Imugene reported its half-year results yesterday. It’s still loss-making, but sharply cutting costs and seeing what appear to be genuinely encouraging clinical results.

Its lead cancer therapy, azer-cel, is showing strong response rates in difficult lymphoma cases, with some patients cancer-free for nearly two years - and the FDA has given positive feedback on the company’s strategy.

But at the same time, the company’s share price is down around 80pc over the last year.

Sean Aylmer speaks to Leslie Chong, CEO and Managing Director of Imugene, about what it takes to run a long-cycle biotech business, trying to develop life-changing treatments while keeping investors engaged.

Biotech company Imugene reported its half-year results yesterday. It&rsquo;s still loss-making, but sharply cutting costs and seeing what appear to be genuinely encouraging clinical results. Its lead cancer therapy, azer-cel, is showing strong response rates in difficult lymphoma cases, with some patients cancer-free for nearly two years - and the FDA has given positive feedback on the company&rsquo;s strategy. But at the same time, the company&rsquo;s share price is down around 80pc over the last year. Sean Aylmer speaks to Leslie Chong, CEO and Managing Director of Imugene, about what it takes to run a long-cycle biotech business, trying to develop life-changing treatments while keeping investors engaged.

Business news you can use. A daily business news podcast with journalists Sean Aylmer and Michael Thompson. Find out more at https://fearandgreed.com.au

Business news you can use. A daily business news podcast with journalists <a href="https://www.linkedin.com/in/sean-aylmer-9922068/" data-saferedirecturl="https://www.google.com/url?q=https://www.linkedin.com/in/sean-aylmer-9922068/&amp;source=gmail&amp;ust=1689199223540000&amp;usg=AOvVaw0wu3ezGEfBZFYspJbTTaYL">Sean Aylmer</a>&nbsp;and&nbsp;<a href="https://www.linkedin.com/in/mcwthompson/" data-saferedirecturl="https://www.google.com/url?q=https://www.linkedin.com/in/mcwthompson/&amp;source=gmail&amp;ust=1689199223540000&amp;usg=AOvVaw08pZ8jZ88rHJgCfbHkTr5k">Michael Thompson</a>.&nbsp;Find out more at&nbsp;<a href="https://protect-au.mimecast.com/s/7AmQCOMxmAtl5q0qiE-KY7?domain=fearandgreed.com.au/" data-saferedirecturl="https://www.google.com/url?q=https://protect-au.mimecast.com/s/7AmQCOMxmAtl5q0qiE-KY7?domain%3Dfearandgreed.com.au/&amp;source=gmail&amp;ust=1689199223540000&amp;usg=AOvVaw1DLq_FuqjEt3HC-ZK1704H">https://fearandgreed.com.au</a>

Fear and Greed is Australia's most popular business podcast.

FEAR & GREED | Business News

Daily business news for people who make their own decisions, with business journalist Sean Aylmer and Michael Thompson. Find out more at https://fearandgreed.com.au

Daily business news for people who make their own decisions, with business journalist <a href="https://www.linkedin.com/in/sean-aylmer-9922068/">Sean Aylmer</a> and <a href="https://www.linkedin.com/in/mcwthompson/">Michael Thompson</a>. Find out more at <a href="https://protect-au.mimecast.com/s/7AmQCOMxmAtl5q0qiE-KY7?domain=fearandgreed.com.au/">https://fearandgreed.com.au</a>